Documentos de Académico
Documentos de Profesional
Documentos de Cultura
• The primary end point (SRI(4) response at Week 24) was met by more patients treated with anifrolumab than
placebo
• This result was significant in the overall population and in patients with a high IFN signature at baseline,
and was maintained to Week 52
• OCS reduction versus placebo was significant in the anifrolumab 300 mg group
Anifrolumab substantially reduced disease activity compared with placebo in patients with moderate-to-severe SLE
Parameter*
0.25 • Brand name:
mg/kg
• Lupkynis1
Tmax (h)
median (range) 1.5 (1–4) • Company:
• Aurinia1
Vss/F (L) 2154
• Drug Class:
CLss/F (L/h) 63.6 • Calcineurin inhibitor1
• Status:
Terminal t1/2 (h) 30 (24.9–36.5)
• US: Approved in combination with background
immunosuppressive therapy for the treatment of adult
Vz/F (L/kg) 15.1 ± 3.4 patients with active LN1
• EU: Initial marketing authorization application filed2
• Dosage and Administration:
23.7 mg
*mean ± SD unless otherwise stated; CL ss/F, apparent total•clearance; V ss/F,orally, twice
apparent a of
1
volume daydistribution
1. FDA. Highlights of prescribing information (Lupkynis) (online). Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf [Accessed
October 2021]; 2. Otsuka. Otsuka Has Filed a Marketing Authorization Application to the European Medicines Agency for Voclosporin for the Treatment of Patients with
Lupus Nephritis (online) Available from https://www.otsuka.co.jp/en/company/newsreleases/2021/20210625_1.html [Accessed October 2021]
AURA-LV: Renal Response at Week 24 in
Patients With Lupus Nephritis
50
Patterned sections denote additional
patients achieving CRR* at Week 48
40
Number of patients
30
20
• Compared with placebo, a significantly greater proportion of patients in the voclosporin groups achieved CRR*
at 48 weeks (P<0.001 for low-dose, P=0.026 for high-dose)
• Patients who achieved CRR* at Week 24 tended to maintain CRR* to Week 48 (Figure)
• Additional patients who did not achieve CRR* at Week 24 achieved CRR* at Week 48